bruno angelici.jpg
  • R
  • A
Tenure

Bruno Angelici was appointed to the Vectura Board on 1 December 2013 and became Non‑Executive Chairman in February 2014.

Experience

Bruno is a French national with an MBA (Kellogg School of Management) and business and law degrees from Reims.

Bruno’s career includes senior management roles in pharmaceutical and medical device companies. Bruno retired from AstraZeneca in 2010 as Executive Vice President International after a 20-year career. He was responsible for Europe, Japan, Asia Pacific, Latin America, the Middle East and Africa having originally joined as president of ICI Pharmaceuticals France. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries.

External appointments

Bruno is a non-executive director of Smiths Group plc, a technology group, and Novo Nordisk A/S, a global healthcare company and world leader in diabetes care. He is also a member of the Global Advisory Board of Takeda Pharmaceutical Company Ltd, Japan, the largest pharmaceutical company in Asia, and a member of the supervisory board of Wolters Kluwer NV, a global information services and publishing company.

Condella-Resized-2016.jpg
  • R
  • A
Tenure

Frank Condella was appointed Vice Chairman on 10 June 2016 upon completion of the merger with Skyepharma PLC.

Experience

Frank Condella had been non-executive chairman of Skyepharma PLC since January 2010, having originally joined Skyepharma PLC as chief executive officer in 2006, stepping down from this role in 2008 and remaining on the board as an executive director until 2008 when he became a non-executive director.

Frank Condella has over 30 years’ experience in the pharmaceutical industry. He is president, chief executive officer and a director of Juniper Pharmaceuticals, Inc. Previously, he was a non-executive director of Fulcrum Pharma Ltd and Prosonix Ltd, president of European operations at IVAX, chief executive officer of Faulding Pharmaceuticals, vice president of the specialty care products business at Roche and vice president and general manager of the Lederle unit of American Home Products (Pfizer). He is a US citizen and holds a BS in pharmacy and an MBA from Northeastern University.

james-ward.jpg
  • R
  • A
Tenure

James Ward-Lilley was appointed Chief Executive Officer of Vectura in September 2015.

Experience

James is a BA Hons graduate, has an MBA and holds an Institute of Marketing Diploma.

Prior to joining Vectura, James was vice president respiratory, inflammation & autoimmunity, Global Product and Portfolio Strategy (GPPS) at AstraZeneca. In this role James had responsibility for the development of AstraZeneca’s Respiratory, Inflammation and Autoimmunity (RIA) strategy which included the acquisitions of Almirall’s respiratory business and Pearl Therapeutics.

Prior to this, James led the AstraZeneca investor relations team from 2011 to 2012.

James had an extensive career at AstraZeneca, spanning 28 years across a variety of commercially focused roles. James progressed from sales and marketing roles in the UK through to country head of Belgium and Luxembourg, a position he held between 2002 and 2005. He then led AstraZeneca’s business in China to become the number one pharmaceutical company in the market in 2008. James went on to become regional vice president for Central Eastern Europe and the Middle East, where the business enjoyed a period of strong growth, with sales doubling to US$2bn during his tenure.

Derrodra-Resized-2016.jpg
  • R
  • A
Tenure

Andrew Derodra was appointed Chief Financial Officer on 10 June 2016 upon completion of the merger with Skyepharma PLC.

Experience

Prior to joining Vectura, Andrew had been chief financial officer of Skyepharma PLC since November 2013. Andrew has spent over 25 years working in senior finance and strategic roles within five FTSE 100 groups, most recently with Tate & Lyle PLC where he was group vice president finance and control from 2011. Prior to that he was with SABMiller PLC, where he held a succession of roles culminating in business transformation director – Europe, before which he was with Diageo PLC, British Airways Plc and Reed Elsevier PLC. He is a Fellow of the Chartered Institute of Management Accountants and holds a BA(Hons) in mathematics from Oxford University.

trevor-philips.jpg
  • R
  • A
Tenure

Dr Trevor Phillips joined the Vectura Board in June 2012. He was appointed Chief Operations Officer in July 2011, having joined the Company in January 2010 as President of US Operations.

Experience

Trevor has a BSc in microbiology from the University of Reading and a PhD in microbial biochemistry from the University of Wales. He was awarded an MBA from Henley Management College in 1997.

Prior to Vectura, Trevor gained extensive international experience in organisational leadership, management and pharmaceutical drug development in a number of senior roles, including positions as CEO and president of the US publicly held company Critical Therapeutics Inc, following six years as the company’s chief operating officer. During his time at Critical Therapeutics, Trevor was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development and NDA filings, commercial product manufacturing and mergers and acquisitions. Between 1986 and 2002 Trevor held a number of management positions at Sepracor, Scotia Pharmaceuticals, Accenture, GlaxoWellcome Research and Development and Simbec Research Limited.

susan-foden.jpg
  • R
  • A
Tenure

Dr Susan Foden joined the Vectura Board in January 2007.

Experience

Susan has held various positions in venture capital and UK biotech companies. From 2000 to 2003 she was an investor director with the London-based venture capital firm Merlin Biosciences Limited, and was chief executive officer of the technology transfer company Cancer Research Campaign Technology Ltd from 1987 to 2000. She studied biochemistry at the University of Oxford from where she obtained an MA and a DPhil.

External appointments

Susan holds a number of non-executive directorships with both public and private companies in the biotech and healthcare field, including BTG plc, BerGenBio AS, the Cell Therapy Catapult and Evgen Pharma plc.

neil-warner.jpg
  • R
  • A

Tenure

Neil Warner joined the Vectura Board in February 2011.

Experience

Neil has significant financial and managerial experience in multinational businesses. He was finance director at Chloride Group plc, a position he held for 14 years until the company’s acquisition by Emerson Electric. Prior to this, he spent six years at Exel plc (formerly Ocean Group plc and acquired by DHL/Deutsche Post in December 2005), where he held a number of senior posts in financial planning, treasury and control. He has also held senior positions in Balfour Beatty plc (formerly BICC Group plc), Alcoa and PricewaterhouseCoopers and was a non-executive director of Dechra Pharmaceuticals plc, where he was the senior independent director and chair of the audit committee. Neil has an economics degree from the University of Leeds and is a Fellow of the Institute of Chartered Accountants.

External appointments

Neil is senior independent director and audit committee chair of Trifast plc, a global leader in design, technology and manufacturing of industrial fasteners for the automotive and technology sectors. Neil was formerly the non-executive chairman of Enteq Upstream plc, a specialist reach and recovery products and technologies provider to the upstream oil and gas services market.

per-olaf.jpg
  • R
  • A
Tenure

Dr Per-Olof Andersson joined the Vectura Board in April 2015.

Experience

Per-Olof was born in Sweden and studied medicine at Lund University. Per-Olof has an international R&D track record within the pharmaceuticals, bio-pharmaceuticals and speciality pharmaceutical industry and considerable experience in respiratory therapeutic development. In 2011, Per-Olof retired from Almirall where he was executive director for R&D and a member of the board of directors. Prior to joining Almirall in 2006, Per-Olof had a distinguished international career at Pharmacia and Pfizer over a period of nearly 20 years. Since 2011, Per-Olof has been an independent consultant advising biotech and pharmaceutical companies and, in particular, working with Almirall.

Werner-Resized-2016.jpg
  • R
  • A
Tenure

Dr Thomas Werner was appointed Non-Executive Director on 10 June 2016 upon completion of the merger with Skyepharma PLC.

Experience

Dr Thomas Werner had been a non-executive director of Skyepharma PLC since May 2009.

Dr Thomas Werner has over 30 years of experience in the pharmaceutical industry, previously as senior vice president of GlaxoSmithKline where he was managing Director for Germany and also co-ordinated their European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and Convatec Germany/Central Europe. Dr Werner sits on the boards of Basilea Pharmaceutica Ltd, Riemser Pharma GmbH, BSN Medical and Blackfield AG. He is chairman of the investor advisory committee of the Seventure (France) Health for Life capital investment fund. Beside his business responsibilities he has previously served for many years on the board of trustees of the Paul Ehrlich Foundation and the Robert Koch Foundation and was a director of the American Chamber of Commerce in Germany representing healthcare companies. He is a German citizen and holds a degree in chemistry from the University of Göttingen.

james-ward.jpg
Tenure

James Ward-Lilley was appointed Chief Executive Officer of Vectura in September 2015.

Experience

James is a BA Hons graduate, has an MBA and holds an Institute of Marketing Diploma.

Prior to joining Vectura, James was vice president respiratory, inflammation & autoimmunity, Global Product and Portfolio Strategy (GPPS) at AstraZeneca. In this role James had responsibility for the development of AstraZeneca’s Respiratory, Inflammation and Autoimmunity (RIA) strategy which included the acquisitions of Almirall’s respiratory business and Pearl Therapeutics.

Prior to this, James led the AstraZeneca investor relations team from 2011 to 2012.

James had an extensive career at AstraZeneca, spanning 28 years across a variety of commercially focused roles. James progressed from sales and marketing roles in the UK through to country head of Belgium and Luxembourg, a position he held between 2002 and 2005. He then led AstraZeneca’s business in China to become the number one pharmaceutical company in the market in 2008. James went on to become regional vice president for Central Eastern Europe and the Middle East, where the business enjoyed a period of strong growth, with sales doubling to US$2bn during his tenure.

Derrodra-Resized-2016.jpg
Tenure

Andrew Derodra was appointed Chief Financial Officer on 10 June 2016 upon completion of the merger with Skyepharma PLC.

Experience

Prior to joining Vectura, Andrew had been chief financial officer of Skyepharma PLC since November 2013. Andrew has spent over 25 years working in senior finance and strategic roles within five FTSE 100 groups, most recently with Tate & Lyle PLC where he was group vice president finance and control from 2011. Prior to that he was with SABMiller PLC, where he held a succession of roles culminating in business transformation director – Europe, before which he was with Diageo PLC, British Airways Plc and Reed Elsevier PLC. He is a Fellow of the Chartered Institute of Management Accountants and holds a BA(Hons) in mathematics from Oxford University.

trevor-philips.jpg
Tenure

Dr Trevor Phillips joined the Vectura Board in June 2012. He was appointed Chief Operations Officer in July 2011, having joined the Company in January 2010 as President of US Operations.

Experience

Trevor has a BSc in microbiology from the University of Reading and a PhD in microbial biochemistry from the University of Wales. He was awarded an MBA from Henley Management College in 1997.

Prior to Vectura, Trevor gained extensive international experience in organisational leadership, management and pharmaceutical drug development in a number of senior roles, including positions as CEO and president of the US publicly held company Critical Therapeutics Inc, following six years as the company’s chief operating officer. During his time at Critical Therapeutics, Trevor was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development and NDA filings, commercial product manufacturing and mergers and acquisitions. Between 1986 and 2002 Trevor held a number of management positions at Sepracor, Scotia Pharmaceuticals, Accenture, GlaxoWellcome Research and Development and Simbec Research Limited.

Geraldine.jpg
Tenure

Dr Geraldine Venthoye joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC where she had been Executive Vice President Pharmaceutical Development since 2013, having joined Skyepharma as Head of Inhalation Business Unit in September 2003.

Experience

Geraldine is a UK registered pharmacist and holds a doctorate degree in Pharmaceutics from the University of London. In 2011, Geraldine was appointed Affiliate Assistant Professor in the Department of Pharmaceutics, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, US.

Previously, Geraldine held senior CMC leadership and scientific roles in Inhale/Nektar Therapeutics, San Carlos, California, US and prior to this in the UK, held scientific positions in inhalation drug delivery at Vandsons Research and Norton Healthcare.

roger-heerman.jpg
Tenure

Roger Heerman joined Vectura in 2010 and was appointed Chief Commercial Officer in 2013.

Experience

Prior to joining Vectura, Roger gained extensive US and international commercialisation experience in a number of senior roles, including vice president sales and marketing of the US publicly held company Critical Therapeutics, Inc. and as vice president, director of client service at McK Healthcare.

At Critical Therapeutics, he was responsible for the build-out of the commercial infrastructure and the launch of ZYFLO CR in the US. At McK Healthcare, Roger supported the launch and repositioning efforts of numerous US and global brands, including UCB’s Neupro® for Parkinson’s disease and IROKO’s Aggrastat® for acute coronary syndrome.

Roger began his career in the pharmaceutical industry as a sales representative in the respiratory division at GlaxoSmithKline. He received his BS from Babson College and his MBA from the F.W. Olin School of Business at Babson College.

David Lescuyer 2016 photo.jpg
Tenure

David joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC where he had been Executive Vice President, Oral Business, since April 2016.

Experience

David, a French national, holds a B.Sc. in Mechanical Engineering and MBA from HEC Paris.

David joined Skyepharma from Patheon Pharmaceuticals where he was Executive Director and General Manager, Patheon France and more recently Global VP, Operational Excellence. Prior to Patheon, David's career included experience with Fareva, Cenexi and Catalent in senior operational and general management roles.

jo-hombal.jpg
Tenure

Joanne Hombal joined Vectura in January 2015.

Experience

Joanne has a BSc in psychology from the University of Birmingham, a postgraduate diploma in human resource management from the University of Glamorgan and is a Chartered Member of the Institute of Personnel and Development.

Before joining Vectura, Joanne was vice president HR at Invensys Rail, with responsibility for setting and leading the people strategy for Northern Europe. She has also held senior HR roles in the financial services and ICT industries and led a number of organisational development and transformation initiatives.

John Murphy.jpg
Tenure

John joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC where he had been General Counsel and Company Secretary since 2006.

Experience

John holds a B.Sc. in Aeronautical Engineering from Bristol University and is a qualified solicitor.

John has extensive experience in legal and company secretarial roles in listed pharmaceutical and biotechnology companies including Medeva PLC, Celltech Group PLC and Pharmagene PLC (now Asterand plc). He is Chairman of the BIA Intellectual Property Advisory Committee and a member of the EuropaBio Intellectual Property Working Group.